Deletion of $Tmtc4$ activates the unfolded protein response causing postnatal hearing loss

Jiang Li, …, Dylan K. Chan, Elliott H. Sherr

*J Clin Invest.* 2018. [https://doi.org/10.1172/JCI97498](https://doi.org/10.1172/JCI97498).

Hearing loss is a significant public health concern, affecting over 250 million people worldwide. Both genetic and environmental etiologies are linked to hearing loss, but in many cases the underlying cellular pathophysiology is not well understood, highlighting the importance of further discovery. We found that inactivation of the gene, $Tmtc4$ (transmembrane and tetratricopeptide repeat 4), which was broadly expressed in the mouse cochlea, caused acquired hearing loss in mice. Our data showed $Tmtc4$ enriched in the endoplasmic reticulum, and that it functioned by regulating $\text{Ca}^{2+}$ dynamics and the unfolded protein response (UPR). Given this genetic linkage of the UPR to hearing loss, we demonstrated a direct link between the more common noise-induced hearing loss (NIHL) and the UPR. These experiments suggested a novel approach to treatment. We demonstrated that the small-molecule UPR and stress response modulator ISRIB (Integrated Stress Response Inhibitor), which activates eIF2B, prevented NIHL in a mouse model. Moreover, in an inverse genetic complementation approach, we demonstrated that mice with homozygous inactivation of both $Tmtc4$ and $Chop$ had less hearing loss than knockout of $Tmtc4$ alone. This study implicated a novel mechanism for hearing impairment, highlighting a potential treatment approach for a broad range of human hearing-loss disorders.

Find the latest version:

[http://jci.me/97498/pdf](http://jci.me/97498/pdf)
Title:

Deletion of Tmtc4 activates the unfolded protein response causing postnatal hearing loss

Authors:
Jiang Li¹, Omar Akil², Stephanie L. Rouse², Conor W. McLaughlin², Ian R. Matthews², Lawrence R. Lustig³, Dylan K. Chan²^ and Elliott H. Sherr¹,4^

Affiliations:

1. Department of Neurology, UCSF
2. Department of Otolaryngology-Head and Neck Surgery, UCSF
3. Department of Otolaryngology, College of Physicians and Surgeons, Columbia University and New York Presbyterian Hospital
4. Department of Pediatrics, Institute of Human Genetics, Weill Institute for Neurosciences, UCSF

^To whom correspondence should be addressed:

Elliott H. Sherr MD PhD
Department of Neurology, UCSF
675 Nelson Rising Lane, Room 214B
San Francisco, CA 94158
Elliott.Sherr@ucsf.edu
(415) 514-9306

Dylan K. Chan MD PhD
Department of Otolaryngology-Head and Neck Surgery, UCSF
513 Parnassus Ave, Rm 719, Box 3213
San Francisco, CA 94143
Dylan.Chan@ucsf.edu
(415) 353-2757

Conflict of Interest Declaration: Drs. Sherr and Chan are founders and shareholders in Jacaranda Biosciences. Dr. Sherr is listed as an inventor on the published patent application: Novel methods of treating hearing loss (PCT/US2016/058348)
Abstract:

Hearing loss is a significant public health concern, affecting over 250 million people worldwide. Both genetic and environmental etiologies are linked to hearing loss, but in many cases the underlying cellular pathophysiology is not well understood, highlighting the importance of further discovery. We found that inactivation of the gene, Tmtc4 (transmembrane and tetratricopeptide repeat 4), which was broadly expressed in the mouse cochlea, caused acquired hearing loss in mice. Our data showed Tmtc4 enriched in the endoplasmic reticulum, and that it functioned by regulating Ca\(^{2+}\) dynamics and the unfolded protein response (UPR). Given this genetic linkage of the UPR to hearing loss, we demonstrated a direct link between the more common noise-induced hearing loss (NIHL) and the UPR. These experiments suggested a novel approach to treatment. We demonstrated that the small-molecule UPR and stress response modulator ISRIB (Integrated Stress Response Inhibitor), which activates eIF2B, prevented NIHL in a mouse model. Moreover, in an inverse genetic complementation approach, we demonstrated that mice with homozygous inactivation of both Tmtc4 and Chop had less hearing loss than knockout of Tmtc4 alone. This study implicated a novel mechanism for hearing impairment, highlighting a potential treatment approach for a broad range of human hearing-loss disorders.
Main Text:

Introduction:

Sensorineural hearing loss, the most common cause of hearing impairment, can result from genetic mutations, noise exposure, aging, or other environmental exposures, including ototoxic drugs such as aminoglycosides and cisplatin. These ototoxic injuries typically share, as their end result, damage and reduction in synapses between sensory hair cells and afferent nerves, apoptotic death of hair cells themselves, and subsequent regression and degeneration of auditory neurons and cochlear supporting cells (1, 2). A number of organ- and cellular-level mechanisms have been implicated in noise-induced hearing loss (NIHL) (3). These include mitochondrial oxidative stress, in which reactive oxygen species are released in the cochlea upon noise exposure; Ca^{2+} overload in hair cells due to excessive entry through ion channels (4); and mitochondrial dysfunction and ischemia leading to ATP depletion (5).

There is currently no effective medical treatment for acquired or genetic sensorineural hearing loss. Small-molecule antioxidants such as N-acetyl cysteine (6) and ebselen (7), a peptide inhibitor of the Jun kinase (8), and L-type Ca^{2+}-channel blockers (9, 10) have been shown to prevent hearing loss in animal models; however, efficacy in human trials has thus far been limited (11, 12). Many of these therapeutics have targets far downstream in the terminal pathways of oxidative stress and apoptosis, which may explain this lack of efficacy. Identification and modulation of additional pathways involved in genetic and acquired hearing loss, particularly those more upstream and proximal to the mechanism of initial cochlear trauma, would be invaluable to reveal new targets for pharmacologic and biologic therapy. Indeed, work by our group and others on genetic animal models of congenital and noise-induced deafness owing to deficiency in VGLUT3 (13) and pejvakin (14), respectively, has led to demonstration of the potential utility of gene therapy in hearing restoration in mice.

In this study, we report characterization of the gene, Tmtc4 (transmembrane and tetratricopeptide repeat 4), that, when genetically inactivated in mice, causes rapid and early post-natal outer and inner cochlear hair cell death, leading to hearing loss. We demonstrate that the protein encoded by Tmtc4 can be found in the same molecular complex with the main endoplasmic reticulum (ER) Ca^{2+} pump, SERCA2b, and through this may alter ER Ca^{2+} dynamics, leading to downstream over-activation of the ER unfolded protein response (UPR) and cell death. We confirm the functional linkage between Tmtc4 and the UPR by conducting a genetic “inverse complementation” experiment, in which combined genetic inactivation of both
Tmtc4 and the ER stress constituent Chop leads to reduced hearing loss when compared to inactivation of Tmtc4 alone. We then demonstrate that these mechanisms are also altered early in the cochlea’s response to acoustic overstimulation and that pharmacological inhibition of this ER stress response rescues a mouse model of NIHL, pointing to both novel mechanisms of and novel treatments for hearing loss.

Results:

Tmtc4-knockout mice have rapid, postnatal-onset hearing loss

ES cells were obtained from the knockout (KO) mouse project repository (www.komp.org) that contained a non-conditional genomic deletion within Tmtc4 via homologous recombination (15) on a C57BL/6J background. This deletion begins at the 5’ end of exon 1 through the 3’ end of exon 3, replaced by a cassette encoding the genes for beta-galactosidase and neomycin (Supplementary Figure #1A). After confirming that these ES cells carried this Tmtc4 interstitial deletion, these cells were then injected into the blastocysts of C57BL/6J (B6) mice. Vertical transmission was confirmed and KO and heterozygous (Het) offspring were viable, and KO/WT/Het mice were born with the predicted Mendelian frequencies. There was no evident morbidity or early mortality, and the KO animals reproduced successfully.

Tmtc4 KO mice have early onset HL when compared to their matched littermate controls. Sound-field click and pure-tone auditory brainstem response (ABR) showed that hearing thresholds measured at post-natal day 13 (P13) were identical between WT, KO and Het mice (Figure #1A). However, by P23 the KO mice were nearly completely deaf (Figure #1A, B, D). Distortion-product otoacoustic emissions (DPOAEs) were also absent, indicating outer-hair-cell (OHC) dysfunction (Figure #1C). Immunohistochemistry of cochlear explants revealed progressive loss of first OHCs and then inner hair cells (IHCs) at the cochlear base in Tmtc4 KO mice compared to WT littermates (Figure #2A, B, D, E), and subsequently at the mid-turn and apex (data not shown). Histologic analysis corroborated this finding of generalized and progressive cochlear degeneration affecting first hair cells, and subsequently the supporting-cell network and spiral ganglion neurons (Figure #2C,F and Supplementary Figure #2). To provide further evidence that inactivation of Tmtc4 is the cause of hearing loss in these mice,
we backcrossed the Tmtc4 mutant allele (that was initially on the B6 background) for ten generations (N10) onto the FVB background, a strain well established for normal hearing thresholds, unlike the B6 mice on which the KO was initially generated (which carries the hearing loss ahl allele (16)). These FVB N10 Tmtc4 +/- mice, when intercrossed to produce Tmtc4 -/- mice, produced viable and healthy offspring of the expected Mendelian ratios. Moreover, as seen in the original B6 line, when ABR thresholds were measured at P23, the KO mice were deaf (ABR waveforms not detected at 85 dB) and the WT and Het mice had normal thresholds (data not shown), providing additional evidence that inactivation of Tmtc4 is the cause of hearing loss.

**Tmtc4 is broadly expressed in the cochlea and enriched in the endoplasmic reticulum**

Immunohistochemistry on cochlear sections from P21 Tmtc4 Het mice demonstrated broad expression of β-gal (as an indirect measure of Tmtc4 expression) driven by the Tmtc4 promoter in IHCs, OHCs, and cochlear supporting cells (Figure #3). This corroborates recently published data from RNASeq and mass spectrometry experiments of flow-sorted outer and inner hair cells confirming that Tmtc4 protein is highly enriched in these cells (17, 18). These published data also demonstrate that the level of Tmtc4 (both mRNA and protein) in the cochlea is higher than the other three isoforms (Tmtc1,2,3), although all four are expressed in the cochlea (18). Given the broad expression of all isoforms in the cochlea and the recently published linkage of TMTC2 to hearing loss in humans (19), we also tested whether inactivation of Tmtc4 led to a change in the abundance of other isoforms. As measured by qPCR, we found that there was a significant increase in the levels of Tmtc1, Tmtc2, and Tmtc3 mRNA in the cochlea of Tmtc4 KO mice compared to littermate WT controls, suggesting possible shared functions (Supplementary Figure #3).

We then assessed the intracellular localization of TMTC4. We stably introduced c-Myc-tagged TMTC4 cDNA into HEK 293 cells and assessed intracellular localization of TMTC4-Myc using antibody to human TMTC4 (Figure #4A). This approach showed overlap of localization of TMTC4 with the ER-resident proteins SERCA2B and GRP94 (89% and 87%, respectively), but minimal overlap was noted with staining of the Golgi marker GM130 (29%), suggesting that TMTC4 was enriched in the ER. We then tested whether native TMTC4 was overrepresented in biochemical fractions enriched in the endoplasmic reticulum from untransfected, WT HEK cells.
We found, as would be predicted, that SERCA2B, Calnexin and Calreticulin were enriched in the ER fraction, but VDAC1, a mitochondrial marker, was not. TMTC4 was found to be enriched in the same cellular fraction as the ER markers (Figure #4B). To further test whether TMTC4 may be an ER-resident protein, we immunoisolated TMTC4-Myc from stably transfected HEK cells and then treated this fusion protein with Endoglycosidase H (Endo H) or Peptide N-Glycosidase F (PNGase F). N-linked glycans are large hydrophilic sugar structures that are added co- or post-translationally to most secretory proteins upon ER targeting. TMTC4 is predicted to have multiple glycan sites by the NetNGly algorithm (20). As shown in Figure #4C, both Endo H and PNGase F lead to a decrease in the apparent molecular weight of TMTC4-Myc, further supporting the hypothesis that TMTC4 is a glycosylated ER resident protein.

Next, we examined the potential interaction partners of TMTC4 in human fetal brain and in HEK cells stably transfected with TMTC4-Myc (Figure #5). From non-nuclear detergent solubilized whole-cell lysate, two known ER markers - SERCA2B and Calnexin, were identified to co-immunoprecipitate with either endogenous TMTC4 from human brain (Figure #5B) or stably transfected TMTC4-Myc (Figure #5A) from human HEK293 cells by using an antibody against human TMTC4. These complementary approaches suggest that TMTC4 is a resident ER membrane protein that complexes with SERCA2B and Calnexin, two ER membrane proteins that mediate Ca\textsuperscript{2+} and UPR dynamics.

**Tmtc4 regulates ER Ca\textsuperscript{2+} dynamics**

The data above suggest that TMTC4 binds to a protein complex that includes the principal Ca\textsuperscript{2+} pump in the ER, SERCA2B, which, by pumping Ca\textsuperscript{2+} into the ER, helps to maintain the approximately 5000-fold Ca\textsuperscript{2+} gradient between the ER and the cytoplasm (21). We thus sought to test the role of Tmtc4 in ER Ca\textsuperscript{2+} dynamics. We measured intracellular cytosolic [Ca\textsuperscript{2+}] in WT and Tmtc4 KO cochleae using live FURA-2 ratiometric Ca\textsuperscript{2+} imaging (22). In neonatal cochlear organotypic cultures, spontaneous intercellular Ca\textsuperscript{2+} waves occur between the supporting cells of the organ of Corti (Figure #6A). Within individual cells, peaks correspond to cytosolic Ca\textsuperscript{2+} increase due to release of Ca\textsuperscript{2+} from intracellular ER stores, followed by a return to baseline, due in part to subsequent Ca\textsuperscript{2+} re-uptake by SERCA2b back into the ER (23). Quantification of the characteristics of these Ca\textsuperscript{2+} peaks - in particular, the decay time from the maximal
cytosolic $[\text{Ca}^{2+}]$ halfway back to the baseline - provides insight into ER $\text{Ca}^{2+}$ reuptake kinetics. In both neonatal and adult cochleae, these $\text{Ca}^{2+}$ waves are thought to be involved in the cochlear response to mechanical and acoustic trauma (22, 24). Thus, we used this model to investigate the role of Tmtc4 in ER $\text{Ca}^{2+}$ reuptake.

Application of 1 µM thapsigargin, an irreversible inhibitor of SERCA2b, which leads to depletion of $\text{Ca}^{2+}$ in the ER, induction of the UPR, and cell death (25), and 10µM CDN1163, a SERCA2b positive allosteric modulator (26), respectively increase and decrease this decay time in wild-type cochlear cultures (Figure #6B,F), demonstrating that $\text{Ca}^{2+}$ peak decay time can serve as a proxy for measurement of ER $\text{Ca}^{2+}$ reuptake. Tmtc4 KO cochleae had significantly increased spontaneous $\text{Ca}^{2+}$ wave frequency and higher $[\text{Ca}^{2+}]_i$ peak levels (Figure #6D,E). Most notably, similar to thapsigargin, Tmtc4 KO cochlea had significantly longer decay time of $[\text{Ca}^{2+}]$ return to baseline (Figure #6C,F). These findings together are all consistent with impaired $\text{Ca}^{2+}$ reuptake into the ER in Tmtc4 KO cochleae, and suggest that Tmtc4 is a necessary component for regulating ER $\text{Ca}^{2+}$ levels.

**TMTC4 participates in ER stress and the unfolded protein response (UPR)**

The aforementioned experiments demonstrated that Tmtc4 KO mice exhibit early post-natal hearing loss and corresponding progressive degeneration of OHCs, IHCs, and supporting cells. We showed that Tmtc4 is an ER resident protein, associates with the $\text{Ca}^{2+}$ reuptake pump SERCA2b, and is involved in ER $\text{Ca}^{2+}$ dynamics. Dysregulation of ER $\text{Ca}^{2+}$ is strongly associated with ER stress and the unfolded protein response (UPR) pathway (27). We hypothesized that the observed hearing loss in Tmtc4 KO mice may be a result of aberrant over-activation of the UPR and subsequent cell death.

To test the role of Tmtc4 in the UPR, we isolated fibroblasts from the skin of newborn mice (WT and KO) and tested for activation of key signaling molecules in the UPR. WT and KO fibroblasts were treated for 2 hours with 1 µM thapsigargin. KO cells showed increased activation of all three arms of the UPR with markers selective for each arm—Chop (reflective of the PERK arm), XBP1 (reflective of the IRE1 arm), and BiP (Figure #7A). Fluorescence-activated cell sorting showed that steady-state Chop protein levels (as a surrogate for the arm of the UPR that more consistently promotes cell death) are significantly higher in KO compared
to WT fibroblasts, with 29.9% (KO) vs 0.5% (WT) of cells having expression levels above threshold, indicating over-activation of the UPR in KO cells even at baseline in the absence of thapsigargin treatment (Figure #7B). These findings were further confirmed by Western blotting of cells treated with thapsigargin for 24 hours. Compared to WT fibroblasts, Tmtc4 KO fibroblasts had significantly higher protein levels of Chop as well as the downstream UPR protein DR5, and the apoptosis marker cleaved Caspase 8. (Supplementary Figure #4;(28)).

We then directly tested whether the UPR was overactivated in cochleae from KO vs. WT mice. Neonatal cochlear cultures were treated with 1 µM thapsigargin or with vehicle for two hours. As was seen in cultured fibroblasts, KO cochleae had greater induction of mRNA for UPR activators compared to WT cochleae (Figure #7C). Additionally, Caspase 3 mRNA was found to be elevated only in thapsigargin-treated KO cochleae, demonstrating relative sensitivity to apoptotic cell death in KO, but not WT cochlea subjected to pharmacologic ER stress in this model (Figure #7C). These data together demonstrate that absence of Tmtc4 leads to over-activation of the UPR and cell death, both in KO fibroblasts and in Tmtc4 KO neonatal cochleae, suggesting that this cellular disruption leads to hearing loss in these mice.

*Noise exposure activates the UPR in wild-type mice*

We hypothesized that activation of the UPR may be a more general mechanism of hearing loss and tested directly whether acoustic overstimulation (as a model for NIHL) results in UPR activation in wild-type mice. 8-week-old wild-type FVB mice were exposed to 8-16 kHz octave-band white noise at 106 dB SPL for 120 minutes to generate a transient threshold shift (TTS) with partial recovery and partial permanent threshold shift (PTS) (22). UPR pathway gene expression was upregulated as measured in the dissected cochleae two hours after completion of noise exposure compared to unexposed mice (Figure #8A). These findings strongly implicate UPR upregulation in the early stages of NIHL. Additionally, Caspase 3 mRNA levels are also elevated in mice exposed to loud noise, further strengthening this association between the UPR, downstream cell death and NIHL (Figure #8A)

*Modulating the UPR prevents hearing loss in both environmental and genetic models*
Given this observed link of the UPR to hearing loss in both genetic and environmental models, we hypothesized that modulating the UPR could protect against hearing loss. Of the three arms of the UPR, the one culminating in the upregulation of Chop is most consistently implicated in promoting apoptotic cell death, and might be a good candidate for pharmacological and genetic modulation (27). ISRIB (Integrated Stress Response Inhibitor) binds to and activates the guanine nucleotide exchange factor (GEF) eIF2B, leading to subsequent inhibition of ATF4 and hence suppression of downstream components of the UPR, including Chop (29, 30). We first assessed whether ISRIB can modulate the UPR in our cell-based models. After 1 µM thapsigargin treatment to induce UPR activation, WT fibroblasts treated with ISRIB showed decreased levels of both CHOP and S-XBP1 compared to fibroblasts treated with thapsigargin alone (Supplementary Figure #5). We then evaluated the ability of ISRIB to attenuate NIHL. WT FVB mice were exposed to the same sound described above, which we showed induces UPR gene upregulation (Figure #8A). 2.5 mg/kg of ISRIB or vehicle was administered intraperitoneally 3 hours prior to noise exposure. ABR thresholds 1, 7 and 14 days post noise-exposure were elevated in both groups of animals, but those treated with ISRIB showed improved hearing at all timepoints, with approximately 30% attenuation of threshold shifts (p<0.05 for each timepoint) (Figure #8B). In addition to this partial rescue of hearing loss, we also observed a corresponding decrease in outer hair cell loss in these same ISRIB-treated and noise-exposed mice (Figure #8C/D).

These findings demonstrated the ability of UPR modulation, specifically inhibition of the Chop arm of the UPR, to prevent hearing loss in an acquired, pharmacologic model (Figure #9A). We next performed a genetic "inverse complementation" assay by breeding Tmtc4 KO mice to Ddit3 (Chop) KO mice. A previous study has shown that Chop KO mice were less susceptible to the deleterious effects of aberrant UPR regulation, providing a strong rationale for this approach (31-33) (Figure #9B). Compared to Tmtc4 KO mice on a Chop WT background, animals that were homozygous for both the Tmtc4 KO and the Chop KO alleles had improved hearing thresholds at P19, although not completely restored, as this may be a result of the more significant impact on the UPR that complete absence of Tmtc4 creates (Figure #9C). This suggests that the Chop KO allele complements the absence of Tmtc4 and decreases the severity of hearing loss, linking these two genes to a shared molecular pathway, and underscoring the importance of the UPR as a potential pathway for treatment for NIHL.
Discussion

We have shown that the gene, Tmtc4, when inactivated, leads to rapid onset postnatal hearing loss with subsequent hair-cell death and cochlear degeneration. We demonstrated that inactivation of Tmtc4 in the mouse cochlea leads to aberrant Ca²⁺ signaling, consistent with delayed reuptake into the ER, and to overactivation of the UPR, as observed by an increase in mRNA and protein levels for key UPR proteins Chop, XBP1 and BiP, and apoptotic proteins DR5 and Caspase 8. Our data show that Tmtc4 is present in cochlear supporting and hair cells, is enriched in the ER, and co-immunoprecipitates with SERCA2b, which strengthens the linkage between the observed aberrant regulation of ER Ca²⁺ and Tmtc4. By use of an inverse genetic complementation approach, we confirmed the importance of the UPR in mediating hearing loss in this genetic model, showing that simultaneous homozygous inactivation of both Tmtc4 and Chop leads to less impaired hearing than with Tmtc4 KO alone. We extended these significant advances underlying the genetics and biology of hearing loss by demonstrating for the first time that NIHL is associated with activation of the UPR, which points to new avenues for treatment for this common disabling condition. We tested this therapeutic hypothesis directly by showing that pharmacological suppression of the UPR with a single dose of the eIF2B-activating (and indirectly ATF4-inhibiting) drug ISRIB considerably lessens hearing loss caused by noise exposure. These compelling findings, through both pharmacological and genetic approaches to treat hearing loss, provide new insights into the mechanisms of hearing impairment and suggest a highly promising target for treatment of one of the most common causes of hearing loss.

Tmtc4 is a gene encoding a predicted 741 amino acid 83 kD protein. Tmtc4 has been found by both proteomic and transcriptomic analyses to be expressed in the developing and young post-natal murine cochlea along with the other three isoforms, which is consistent with our data (17, 18, 34). Moreover, our finding that Tmtc1, Tmtc2, and Tmtc3 all increase significantly in transcript abundance in cochleae from Tmtc4 KO mice appears to underscore the likely interrelatedness of these genes. This connection may extend to hearing loss in patients as well. In parallel with our work recently, a missense mutation (rs35725509; Val136Ile) in the human
ortholog TMTC2 was linked to non-syndromic sensorineural hearing loss both in a six-generation family and in a cohort of unrelated individuals with SNHL (179 affected vs. 186 matched controls) (19, 35). This mutation was also recently identified in another family dyad with hearing loss (35). Inactivation of Tmtc4 in a recently published large scale genomics manuscript concurrent with our work, was confirmed by a separate group to result in hearing loss, linking this class of proteins more strongly to hearing impairment (36). TMTC4 encodes ten putative transmembrane domains and eight TPR (tetratricopeptide repeat) domains (Supplementary Figure #1D). TPR domains have been implicated in the generation and regulation of many multi-protein complexes in cellular processes such as transcription and protein degradation. The UPR chaperone protein, P58(IPK) also has nine TPR repeat motifs, and these repeat domains are necessary for the protein’s chaperone activity (37). Thus, by comparison, it is possible that the TPR repeats in TMTC4 may sense unfolded proteins and regulate Ca^{2+} signaling through this mechanism. TMTC4 also contains an ER retention signal, which may help locate the protein to the ER, and hence to regulate Ca^{2+} flux and the unfolded protein response. The TMTC4 protein is highly conserved from mammals to fish and invertebrates, but is not present in plants, fungi or bacteria. TMTC4 is one of four genes in this family, diverging evolutionarily from the paralogs TMTC1-3 approximately 1.2 billion years ago. Despite this more distant divergence, there is still evidence of potential shared functions. Like TMTC4, both TMTC1 and TMTC2 are enriched in the ER and co-immunoprecipitate with SERCA2B (38). There is preliminary large-scale GWAS evidence linking TMTC1, TMTC2 and TMTC4 to type 2 diabetes, a disease whose pathogenesis has been linked strongly to ER stress and the UPR (39, 40). Separately, a recent study suggested that the Tmtc class of proteins may also function as components of an O-mannosylation pathway that selectively glycosylates cadherins and protocadherins, many of which, especially Cdh23, play critical roles in hair-cell function and have also been tied to ER stress and the UPR (41, 42). Further study into the precise role of TMTC family members, and particularly TMTC4, in O-mannosylation, ER Ca^{2+} flux, and the UPR in the cochlea would yield valuable insight into this important pathway.

The UPR is an essential component of cell homeostasis. In response to such stressors as excessive protein synthesis, this UPR pathway can be activated in a manner that slows protein synthesis and promotes cell survival (43, 44). However, if the UPR is overactivated, this aberrant signaling can lead to cell death. There is precedence for involvement of the UPR in genetically defined disorders associated with hearing loss. One disorder, Wolfram syndrome,
presents clinically with diabetes insipidus, diabetes mellitus, optic atrophy and deafness (also referred to as DIDMOAD syndrome). One of the genes for this disorder, WFS1, has been implicated in ER stress through multiple mechanisms, including binding to and regulating the ER Ca²⁺ pump SERCA2B (45). Thus, this disorder links diabetes, deafness and neuronal cell loss to ER stress. A related disorder, Darier-White disease (DWD), is caused by autosomal dominant mutations in the gene ATP2A2, which encodes the same SERCA2B ER Ca²⁺ pump (46, 47). In the general population, this protein is highly intolerant of loss of function mutations as assessed by data from the exome aggregation consortium (EXAC.broadinstitute.org), and there are no reports of patients with homozygous mutations. DWD presents typically with painful mucosal and skin lesions (46) and sometimes deafness, further strengthening the linkage that we observe with TMTC4 (47). While these associations show more direct linkage of the UPR to hearing loss, there are also examples where indirect activation of ER stress occurs in deafness syndromes. For example, in Usher syndrome, which can be caused by mutations in proteins encoding Cdh23, Harmonin and Myo7a, mutated isoforms of these genes prevent the preassembly of this plasma membrane protein complex in the ER, leading to activation of ER stress and subsequent apoptosis (42). Thus, these examples provide both indirect and direct evidence linking ER stress and the UPR to hearing loss. Moreover, there is also data linking age-related hearing loss to the UPR (48) (17).

Our work with TMTC4 further strengthens the connection between the UPR and hearing loss, but also implicates the even more upstream pathway of Ca²⁺ regulation, which may be a potentially more advantageous point for therapeutic intervention. Activation of intercellular Ca²⁺ signaling (ICS) waves in cochlear supporting cells, which are dependent upon Ca²⁺ flux into and out of the ER, have been implicated as an early mechanism in cochlear trauma, analogous to their well-studied role in neurodegeneration. In both neonatal cochlear cultures and, more recently, mature-hearing cochlear explants, ICS waves are triggered within minutes of mechanical and acoustic trauma (22, 24). In this study, we have found that properties of these ICS waves are altered in Tmtc4-deficient mice in ways consistent with impaired Ca²⁺ re-uptake: cytosolic Ca²⁺ clearance is delayed, and ICS waves are more frequent. Modulation of ER Ca²⁺ dynamics, therefore, may be a promising avenue for hearing-loss therapeutics, as has been shown recently in other UPR-dependent disease models; for example, an allosteric activator of SERCA2b, CDN1163, attenuates the development of insulin resistance (type II
diabetes) in the Ob/Ob mouse (26). Current efforts to treat NIHL focus on relatively distal aspects of eventual cell death, such as apoptosis; however, these biological processes may be too late to be effectively controlled. In contrast, the early stages of the UPR, including regulation of ER Ca^{2+}, may be a more viable site for intervention; we demonstrate in this study that upregulation of UPR genes occurs within 2 hours of noise exposure. TMTC4, as a key player in the early stages of cochlear trauma, may be a promising and specific target for drug development for hearing loss.

Methods

Study Design:

The primary goals in this study were the following: 1A. to evaluate the phenotype of hearing loss in Tmtc4 KO mice; 1B. to demonstrate that KO of Tmtc4 in two independent genetic backgrounds still yielded the same hearing deficit; 2. to assess what impact absence of Tmtc4 has on ER Ca^{2+} signaling and downstream activation of the UPR; 3. to test whether Tmtc4 interacts with ER membrane proteins to further strengthen this hypothesis; and 4. to assess whether modifying the UPR signaling pathway can diminish the observed hearing loss in either a genetic or environmentally acquired hearing-loss model (noise exposure). In all experiments, animals were randomly assigned to experimental or treatment groups and matched for age, sex, and littermate controls. All measurements (hearing thresholds, Ca^{2+} signaling, biochemistry, and histological analyses) were carried out blind to genotype and treatment groups.

Mouse genetic models

ES cells were obtained from the knockout (KO) mouse project repository (www.komp.org) that contained a non-conditional genomic disruption of Tmtc4 via homologous recombination (15) beginning at the 5’ end of exon 1 through the 3’ end of exon 3, replaced with a cassette containing beta-galactosidase and neomycin (Supplementary Figure #1A). We confirmed that the ES cells carried this deletion of Tmtc4 by PCR; these cells were then injected into the blastocysts of C57BL/6J mice. Chimeric pups were tested via coat color and testing of tail DNA. Vertical transmission was confirmed in the subsequent generation through testing of
offspring. KO and heterozygous (Het) offspring were viable and KO/Het/wild-type (WT) mice were born with the predicted Mendelian frequencies. *Tmtc4* KO mice were then crossed onto an FVB/NJ (FVB) background to avoid the age-related hearing loss (Ahl) phenotype associated with the C57BL/6J (B6) line. Chop KO mice were obtained from Jackson Laboratory (*Ddit3*tm2.1Dron; strain 005530). All animal protocols were approved by the UCSF Institutional Animal Care and Use Committee (http://iacuc.ucsf.edu).

**Tmtc4 KO fibroblasts and transgenic cell lines**

For in vitro evaluation of the pathophysiologic effects of *Tmtc4* deficiency, we generated stable fibroblast cell lines from postnatal-day 3 (P3) WT and *Tmtc4* KO mice. Briefly, a skin sample from the axillary region is collected and cut into 1 mm pieces. Samples are then digested in 0.14 Wunsch units/mL Liberase Blendzyme 3 in 37°C for 30 minutes. After washing in complete media, the sample pellets are resuspended in DMEM/F12 media with 10% FBS, transferred to a 10-cm tissue culture dish and placed in a tissue culture incubator at 37°C/5%CO2 (49).

In order to perform further biochemical investigation of TMTC4 expression and localization, we performed transfection of HEK 293/T17 cells (CRL-11268, ATCC) HEK cells were transfected with pIRES-EGFP-puro (45567, Addgene) into which the human cDNA for a cMyc-tagged TMTC4 (TMTC4-Myc) was subcloned. For stable transfection, HEK single-cell clones were picked and expanded after puromycin selection. We also generated a TMTC4 KO HEK cell line to use as a negative control for these cell-line based experiments (Supplementary Figure #1B/C). The targeted DNA probe on TMTC4 exon1 was selected by the CRISPR Design Tool (http://tools.genome-engineering.org) and appended onto the U6 primer. HEK cells were co-transfected with the Cas9 expression plasmid (pSpCas9) and a PCR-amplified U6-driven sgRNA expression cassette. The transfected cells were clonally isolated and expanded for genotyping analysis of deletion events. Loss of the TMTC4 protein in ER-enriched fractions was assessed by western blotting (Supplementary Figure #1C).

**Organotypic cochlear cultures**

Organotypic cultures from P3-5 mice of indicated genotypes were established as described (22). Briefly, P3 mice were euthanized and decapitated. Dissection was performed in
dissecting solution (DS; 145 mM NaCl, 3 mM KCl, 0.25 mM CaCl2, 0.25 mM MgCl2, 2 mM Na-pyruvate, 5 mM D-glucose, 10 mM Na2HPO4, pH 7.35). The cochlear duct was isolated, opened, and plated on glass coverslips with Cell-Tak (Corning) with the apical surface of the epithelium facing up. Cultures were incubated overnight at 37°C and 5% CO2 in DMEM-F12 + 10% FBS and 50 mg/mL ampicillin, and used for experiments after 24 hours in culture.

Analysis of TMTC4 localization

For immunofluorescent evaluation of TMTC4 localization, HEK cells were grown in DMEM supplemented with 10% fetal calf serum, 100 units/ml penicillin, and 100 mg/ml streptomycin and incubated at 37 °C in 5% CO2. Cells were transfected with the aforementioned TMTC4-Myc plasmid and selected with puromycin. For staining, cells were dissociated into single cell culture and incubated on glass coverslips. 48 hours later the cells were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 10 minutes at room temperature followed by permeabilization with methanol for 10 minutes at 20 °C. Slides were stained with the indicated primary antibody followed by staining with the appropriate Alexa Fluor 488 or 594 secondary antibodies (A11029 and A11012, Thermo Fisher Scientific). Slides were rinsed and mounted with coverslips using VectaShield (Vector Laboratories). Images were obtained with Carl Zeiss Axio Observer inverted microscope. The primary antibodies used were against human TMTC4 (HPA016489, Sigma), SERCA2B (ab2861, Abcam), GRP94 (ab2791, Abcam), and GM130 (610822, BD Biosciences).

Subcellular localization and co-immunoprecipitation were performed in WT HEK cells, and in HEK cells stably transfected with TMTC4-Myc fusion plasmid, or with empty plasmid. Cells were suspended in hypotonic extraction buffer (10 mM HEPES, pH 7.8, 25 mM KCl, 1 mM EGTA, and protease inhibitor) for 30 minutes at 4°C, centrifuged at 600g for 5 minutes. For non-nuclear whole-cell lysate, the cell pellet was suspended in isotonic buffer (ISO; 10 mM HEPES, pH 7.8, 250 mM sucrose, 25 mM KCl, 1 mM EGTA and protease inhibitor) and transferred to a 7 ml Dounce homogenizer. Cells were broken with 10 strokes of the Dounce homogenizer and the percent of broken cells checked by light microscopy. The homogenate was centrifuged at 650g for 10 minutes twice and the post nuclear supernatant (PNS) collected. For isolation of ER-enriched fractions, the cell pellet was homogenized in ice-cold buffer with 225 mM mannitol, 75 mM sucrose, 0.1 mM EGTA and 30 mM Tris–HCl, pH 7.4, The
homogenate was subjected to a series of centrifugation steps to achieve an ER-enriched cellular sub-fraction as previously described (50).

For co-immunoprecipitation experiments, 500 µg of the aforementioned PNS homogenate was incubated with agarose beads coupled with antibodies to TMTC4 (HPA016489, Sigma), or with beads alone as a negative control, and placed in spin columns (Pierce Biotechnology). Proteins that bound to this linked antibody (the eluate) were detected by immunoblotting with antibodies against c-Myc, SERCA2B, and Calnexin. The Odyssey infrared system (Li-Cor Bioscience) was used for qualitative and quantitative western-blot image analysis. Western blotting was performed using an Odyssey infrared imaging system (Li-Cor Bioscience). Briefly, total protein was isolated from fibroblast cells, separated by electrophoresis on 4-20% gradient tri-glycine gels (Bio-Rad), and then transferred to PVDF (poly vinylidene fluoride; Milipore Sigma). Antibodies used for detection were as follows: primary antibodies: mouse anti-Chop (Ma1-250, Thermo Fisher Scientific), rabbit anti-DR5 (ab8416, Abcam), rabbit anti-caspase8 (9429, Cell Signaling Technology), and mouse anti-beta actin (3700, Cell Signaling Technology); and infrared-labeled secondary antibodies: goat anti-mouse IRDye 800CW (926-32210, Li-Cor Biosciences) or goat anti-rabbit IRDye 680RD (926-68071, Li-Cor Biosciences). The bound complex was detected using the Odyssey infrared imaging system, and images were analyzed using the Odyssey Application Software, version 1.2 (Li-Cor Biosciences).

The ER fraction and non-nuclear whole-cell lysate were also subjected to western-blot analysis as described above. The same approach of co-immunoprecipitation of TMTC4-associated proteins was used with human fetal brain tissue (approval for tissue donation was obtained from the UCSF Institutional Review Board (https://irb.ucsf.edu)).

The glycosylation pattern of TMTC4 was assessed. HEK293T cells stably expressing TMTC4-Myc were lysed and homogenized as described above. The whole-cell non-nuclear lysate was isolated by centrifugation at 650g for 10 minutes. Microsomes were pelleted after centrifugation at 100,000g for 20 minutes. The pellets were suspended in isotonic buffer (ISO). An additional 1% of NP-40 was added to the suspension containing 1mg of protein lysate to a final volume to 400 µl. The lysate was pre-cleared with empty agarose beads. To extract TMTC4 and bound proteins, this cleared lysate was incubated overnight with antibody to c-Myc coupled to agarose beads. The next day these beads were washed three times with ISO
buffer and glycosylation assays were performed using Endoglycosidase H (Endo H) or Peptide N-Glycosidase F (PNGase F) according to the NEB (New England Biolabs) protocol. Finally, reducing sample buffer was added to all samples, and analyzed by western blot with mouse antibody to c-Myc (3700, Cell Signaling Technology).

**UPR gene expression analysis**

Expression of mRNA for ER stress markers (CHOP, S-XBP1 and BiP) was quantified in cultured fibroblasts, cell lines, organotypic cochlear cultures, and adult mouse cochleae. Tmtc4 KO and WT cultured fibroblasts or organotypic cochlear cultures were treated with DMEM-F12 or DS, respectively, or with media containing 0.5 μM thapsigargin, for 2 hours, then harvested onto dry ice. 8-week-old WT FVB mice (001800, Jackson laboratories) were exposed to 106-dB octave-band noise for 2 hours. Two hours after completion of noise exposure, animals were euthanized and cochleae harvested onto dry ice.

Total RNA was isolated using the Purolink RNA mini Kit (Life Technologies), and 1μg total RNA was used for first-strand cDNA synthesis using the SuperScript IV VILO master mix (Invitrogen). Real-time PCR was performed by 7900HT FAST Real-time PCR system (Applied Biosystems) with a SYBR green I mix. The primers for mRNA to ER stress markers are: *Chop*: CCACCACACCTGAAAGCAGAA, AGGTGAAAGGCAGGGACTCA; *S-XBP1*: CTGAGTCCGAATCAGGTGCAG, GTCCATGGGAAGATGTTCTGG; and *BiP*: TTCAGCCAATTATCAGCAAACTCT, TTTTCTGATGTATCCTCTTCACCAGT. Additional quantification was performed for caspase 3 (GGAGAACAACAAAAACCTCAGTGGATTC,CATTCCAGTGCTTATGGAAGTTCTTATTATTA). Relative quantification by the $2^{-\Delta\Delta CT}$ method was used for analysis of real-time PCR data as described previously (51). Briefly, this method directly uses the CT information generated from a qPCR system to calculate relative gene expression in target and reference samples, using an internal control or house-keeping gene (GAPDH) as the normalizer. The first $\Delta CT$ is the difference in threshold cycle between the target and internal control genes; The $\Delta\Delta CT$ is the difference in $\Delta CT$ as described in the above formula between the target and reference samples; for this study, the reference sample consisted of unexposed cells, cochlear cultures, or animals compared to the target, exposed samples.
For flow cytometric analysis of Chop expression, WT or Tmtc4 KO fibroblast cells were collected by trypsin digestion to obtain a single cell suspension, quenched by washing with complete media and centrifuged. The pellet was fixed in 4% formaldehyde in PBS for 10 minutes at 37°C followed by permeabilization in ice-cold 100% methanol for 30 minutes. Cells were washed in PBS with 0.5% BSA and labeled with mouse anti-Chop antibody (MA1-250, ThermoFisher Scientific) or with mouse isotype control (ab37355, Abcam) for 1 hour at room temperature. The cells were then labeled with goat anti-mouse IgG2b secondary antibody, Alexa Fluor 594 (A21145, ThermoFisher Scientific) for 30 minutes. Labeled cells were resuspended in 0.5 ml PBS and run on a BD FACSaria II flow cytometer using FACSDiva software (BD). For quantitative comparison of Chop expression between WT and Tmtc4 KO cells, gating threshold was set at a level 3 SD above the mean fluorescence of WT stained cells.

*Auditory testing and noise exposure*

Hearing was tested in mice, including B6 and FVB Tmtc4 KO/het, B6 Chop/Tmtc4 double KO, and FVB WT mice in vivo by measuring auditory brainstem response (ABR) thresholds in response to broadband clicks and tone pips, and distortion-product otoacoustic emissions (DPOAEs) in the sound field using a standard commercial system (RZ6, Tucker-Davis Technologies) in a soundproof chamber (13, 22). We examined the effect of acoustic overstimulation in 8-week-old WT FVB mice of both sexes in vivo. Hearing was tested at baseline and 1, 7, and 14 days after noise exposure. Animals were exposed to 106-dB octave-band (8-16 kHz) white noise for 120 minutes in a custom-built, calibrated, reverberant sound chamber (22). Animals were not anesthetized in order to avoid the effects of general anesthesia on sound-induced threshold shifts (52). To assess the effect of UPR modulation on NIHL, we pre-treated animals with ISRIB prior to noise exposure. Mice were injected intraperitoneally 3 hours prior to noise exposure with a single dose of 2.5 mg/kg ISRIB (Sigma) or vehicle (50% DMSO, 50% PEG-400). Noise exposure and ABR testing proceeded as described above. All ABR measurements were performed by an investigator blinded to the treatment (ISRIB or vehicle).

*Ca²⁺ imaging*
To evaluate intracellular Ca\textsuperscript{2+} concentration [Ca\textsuperscript{2+}], ratiometric imaging was performed using FURA-2-AM (Thermo Fisher Scientific), a cell-permeant dye, in Tmtc4 KO and WT neonatal organotypic cultures (22). For FURA-2, the ratio of emission stimulated upon 340- and 387-nm excitation is proportional to [Ca\textsuperscript{2+}], Owing to different Ca\textsuperscript{2+}-dependence of its excitation spectra in response to 340 and 387-nm light, the ratio of emission stimulated upon 340- and 387-nm excitation is proportional to [Ca\textsuperscript{2+}] and independent of dye concentration, facilitating stable imaging of intracellular [Ca\textsuperscript{2+}]. Cochleae were loaded by incubation with 16 μM FURA-2-AM in DS + 0.01 w/v Pluronic F-127 and 250 μM sulfinpyrazone for 15 minutes at RT, followed by a 10-minute wash in DS at 37° for de-esterification. Alternating excitation at 340 and 387 nm was performed using a high-speed fluorescence light source, filter wheel, and shutter (Lambda XL, Sutter Instruments), and emission at 510 nm was recorded using a high-speed CMOS camera (ORCA-Flash4.0, Hamamatsu). Imaging was performed with a 60x, 0.80-NA, water-immersion objective on an upright microscope (BX-51, Olympus). 10 ms exposure time at 3 s intervals was used to avoid photobleaching. The ratio of emission stimulated upon 340- and 387-nm excitation (proportional to [Ca\textsuperscript{2+}]), and was measured in regions of interest (ROI) using MetaFluor (Molecular Devices). A total of 225 ROIs were defined on a 100 μm\textsuperscript{2} grid encompassing the entire cochlear epithelium, such that each ROI encompassed a 7x7 μm\textsuperscript{2} area slightly larger than a single cell. Peaks in cytosolic Ca\textsuperscript{2+} levels were detected using a custom peak detector (MatLab), which permitted the extraction of individual peak height (increase in fluorescence ratio from baseline to peak maximum), individual peak decay time (time from peak maximum to half-maximal value), and aggregate peak frequency (number of peaks per minute). Cultures were imaged and recorded for a total of 30 minutes. Thapsigargin (Sigma) and CDN1163 (Tocris Bioscience), respectively an inhibitor and activator of SERCA2b, were used to modulate Ca\textsuperscript{2+} dynamics. For drug application, baseline recording was obtained for 5 minutes in DS, followed by bath application of DS + drug(s) as indicated and further imaging for 30 minutes. All parameters measured in the presence of drug were normalized to the parameters measured during the baseline acquisition period.

\textit{Tmtc4 expression and deficiency in the cochlea}

Morphological differences attributable to Tmtc4 deficiency were examined by light microscopy of stained thin sections. Tmtc4 KO mice and WT littermates at indicated ages were
anesthetized, and their cochleae were isolated, dissected, perfused through the round and oval windows with a solution of 2.5% paraformaldehyde and 1.5% glutaraldehyde in 0.1M phosphate buffer (PB) at pH 7.4, and finally incubated in the same fixative overnight at 4°C. The cochleae were rinsed with 0.1 M PB and post-fixed in 1% osmium tetroxide for 2 hours. The cochleae were subsequently immersed in 5% EDTA for decalcification. The decalcified cochleae were dehydrated with ethanol and propylene oxide and then embedded in Araldite 502 resin (Electron Microscopy Sciences). The cochleae were then sectioned at 5 µm thickness parallel to the cochlea modiolus. The sections were stained with toluidine blue and mounted with Permount (Fisher Scientific) on microscope slides and visualized with a Leica microscope.

Cell specific expression of Tmtc4 was evaluated with beta-galactosidase (β-gal) protein staining. Tmtc4 Het mouse littermates at P21 were anesthetized, and their cochleae were visualized, dissected, and then perfused through the oval and round windows by 4% paraformaldehyde in 0.1 M PBS, pH 7.4. The isolated cochleae were then incubated in the same fixative for 2 hours. After fixation, cochleae were rinsed with PBS and immersed in 5% ethylenediaminetetraacetic acid (EDTA) in 0.1 M PBS for decalcification. Decalcified cochleae (24-36 hours) were embedded in paraffin and 5 µm-thick slices cut in a microtome for immunohistochemistry. These sections were incubated in β-gal antibody (A11132, Thermo Fisher Scientific) overnight, rinsed with PBS, and incubated with biotinylated secondary antibody (BA-110, Vector Laboratories) for one hour. For peroxidase detection, VECTASTAIN Elite ABC kit (PK-6100, Vector Laboratories) and ImmPact DAB kit (SK-4105, Vector Laboratories) were used according to the manufacturer’s instructions.

Evaluation of hair-cell loss was performed with whole-mount cochlear immunohistochemistry. Cochleae from Tmtc4 KO mice and WT littermates at varying time points were isolated, fixed and decalcified as described above. Following decalcification, the otic capsule was then removed, followed by removal of the lateral wall, Reissner’s membrane, and tectorial membrane. The remaining organ of Corti was incubated with anti-myosin VIIa antibody (a hair-cell-specific marker; 1:50 dilution in PBS; 25-6790, Proteus Biosciences) and incubated overnight at 4°C. Whole-mount cochleae were rinsed twice for 10 min with PBS and then incubated for 2 hours with a goat anti-rabbit IgG antibody conjugated to Cy2 (1:2000 dilution in PBS; 111-165-003, Jackson Immuno-Research). Whole mounts were rinsed in PBS twice for 15 min and incubated with rhodamine–phalloidin (stock solution of 200 U/ml methanol, diluted
1:100 in PBS for working solution) for 1 hour. Whole mounts were then rinsed with PBS, further microdissected into individual turns for surface preparation, and then exposed for 15 minutes at room temperature to fluorescent DAPI to mark nuclei. Cochlear whole mounts were rinsed in PBS and mounted on glass slides in antifade FluorSave reagent (34589, Calbiochem). Hair cells in the organ of Corti were visualized by confocal microscopy.

Expression levels of Tmtc isoforms 1-4 were compared in WT and Tmtc4 knockout mouse cochleae at P21 using quantitative PCR. Preparation of RNA from mouse cochlea and qPCR were as described above. Primers used for respective genes:

- Tmtc1 (ATGCTGGTGACCCCGGGGA, CCTTGCCCCAGAAGTCGTTAG),
- Tmtc2 (AGAGAGTGCAGAGTGGCCGGTAG, ATGATTGCAGAGTTGGTGAGCAGCG),
- Tmtc3 (ATGCTTTGAAGGGAAGATGGCTGATATTAACTT, GTGGCTTCTCTCCCTAGACCATAGG), and
- Tmtc4 (ATGGTTGAGCTGGATGCTGACTTGGA, GAAGTCATGGTGCCACAGGTCCC).

**Statistical Analyses**

For comparison between treatment groups for UPR gene expression, we used one-way ANOVA followed by Tukey multiple comparison tests. For pairwise comparison of ABR thresholds and DPOAE levels between groups of mice, and for comparisons of fluorescence levels and Ca²⁺ peak parameters between Ca²⁺ imaging experiments, we used unpaired two-tailed Student’s t-test. Unless otherwise mentioned, results are presented as means +/- SD with sample sizes and p values between designated comparison groups as indicated in the figure legends, with a p-value <0.05 as significant, and lower p values indicated for specific comparisons. Statistical analyses were performed with GraphPad and Matlab.

**Author contributions:** Initial design: EHS, JL, LRL, OA and DKC. Experimental and ethical oversight: EHS and DKC. Experimental contributions: JL, OA, SLR, CWM, IRM, and DKC. Data and statistical analysis: JL, OA, DKC and EHS. Manuscript drafting: EHS, JL, OA, LRL, DKC.

**Acknowledgements:** We would like to thank Peter Walter and Robert Edwards for a careful reading of the manuscript. This work was supported in part by a grant from the NINDS to EHS (2R01NS058721), from the NIDCD (R03DC015082) to DKC and from the NIH/NCATS
Study Approval: The UCSF Institutional Animal Care and Use Program (IACUC: iacuc.ucsf.edu) has provided approval for animal studies in the laboratories of Drs. Sherr and Chan. No human studies were performed for this manuscript.

References:


**Figures:**

**Figure 1.** Rapidly progressive postnatal hearing loss in Tmtc4 KO mice. **A.** At postnatal day 13 (P13), auditory brainstem response (ABR) thresholds to broadband click stimuli are equivalent in Tmtc4 KO (red squares), Het (blue triangles) and WT (black circles) littermates. Tmtc4 KO mice progress to profound deafness by P26. N=4 for each genotype. **B** Hearing loss in P26 Tmtc4 KO mice is present in response to both broadband click and a range of pure-tone frequencies. N=4 for each genotype. **C.** Distortion-product otoacoustic emissions (DPOAEs) measured at different frequencies demonstrate cochlear dysfunction in P26 Tmtc4 KO mice. N=4 for each genotype. **D.** ABR waveforms in P26 Tmtc4 KO and WT littermates demonstrate absent ABR responses to click stimuli at multiple sound pressure levels (SPL) in KO mice. Traces representative of at least 4 experiments. Data represent means and SD. * p < 0.01, ** p < 0.001 by two-tailed, unpaired t test.
Figure 2. Progressive hair-cell loss in Tmtc4 KO mice. Staining for Actin (red; phalloidin), Myosin7a (green), and nuclei (blue; DAPI) demonstrates progressive loss of outer (OHC) and inner hair cells (IHC) in the cochlear base from Tmtc4 KO mice at P10 (A), P30 (B), and P45 (D). Cochlea from a P30 WT mouse is shown for comparison (E). Histologic sections from P26 organ of Corti in WT (C) and KO (F) mice show disrupted architecture in the KO cochlea. Images representative of at least 4 experiments each. Scale bar = 10 \( \mu \text{m} \) (A,B,D,E); 50 \( \mu \text{m} \) (C,F).
Figure 3. Expression of Tmtc4 and its isoforms in mice. In heterozygous TMTC4 KO mice, β-gal expression is driven in the KO allele by the TMTC4 promoter. β-gal expression is seen broadly in the cochlea, particularly in the stria vascularis (SV), spiral ligament (SLg), and organ of Corti (OC), with less expression noted in the spiral limbus (SLm) and spiral ganglion (SG). B. In a magnified view of A, the organ of Corti contains inner (IHC) and outer (OHC) hair cells, as well as supporting cells (pillar cells (PC), Dieter’s cells (DC), and Claudius cells (CC)), with robust labelling. C. WT control mice, in which TMTC4 promoter-driven beta-gal expression is not present, shows no b-gal antibody labeling, demonstrating that the broad labelling seen in A and B is specific.
Figure 4. TMTC4 enrichment in the ER and co-localization with ER markers. A. HEK cells were stably transfected with TMTC4-c-myc constructs and stained with antibodies to TMTC4 (green, leftmost column), ER proteins (GRP94 or SERCA2b), or the Golgi-enriched protein GM130 (red, second column), and DAPI to stain nuclei (blue, all panels). As demonstrated in the merged panels (third column), TMTC4 co-localizes with ER proteins but not with the Golgi protein (quantified in the rightmost column). Images are representative of 5 experiments. Scale bar = 10 μm. B. Non-nuclear whole cell lysate (Whole cell lysate) from wild-type HEK cells, and
a fraction enriched for ER membranes (ER Fxn), were stained with antibodies to TMTC4, as well as to the known ER resident proteins SERCA2b, calnexin, and calreticulin; all showed enrichment in the ER. As controls, actin was not enriched, and the mitochondrial membrane protein VDAC1 was barely detected, in the ER fraction. Quantification of expression levels (relative to actin, and normalized against the relative expression level in whole-cell lysate) confirm the ER localization of endogenous TMTC4 (N=3 experiments, from which representative images were taken) C. TMTC4-c-Myc and co-purifying proteins were isolated from a post-nuclear supernatant of HEK cells with stably incorporated TMTC4-c-Myc vector. This lysate (c-Myc lysate) was then treated with or without Endo H and/or PNGase F and the fractions assessed with antibody to c-Myc. The shift in molecular weight in TMTC4 treated with both Endo H and PNGase F indicates that TMTC4 is glycosylated, consistent with residence in the ER. M: molecular weight markers. Images are representative of 3 experiments.
Figure 5. TMTC4 co-immunoprecipitation with ER membrane proteins. A. Non-nuclear whole cell lysates from HEK cells with stably incorporated TMTC4-c-Myc vector (HEK-TMTC4) or empty plasmid (HEK) were assayed with antibodies to ER proteins (SERCA2b, Calnexin) or TMTC4, showing that all three proteins were present in transfected HEK cells and that the TMTC4 antibody did not stain non-specifically in mock-transfected cells. These extracts from TMTC4-c-Myc stably transfected cells were then incubated with agarose beads linked with antibodies to c-Myc or to beads alone (Beads). Bound proteins were purified and the “pull down” fraction stained with the aforementioned antibodies to TMTC4 and ER proteins, showing that SERCA2b and Calnexin are co-purified upon c-Myc pulldown. Images are representative of 3 experiments. B. Human fetal brain lysate was used to assess endogenous TMTC4 interactions. Pull-down fractions were isolated using beads linked to antibody against SERCA2b, Calnexin, or beads alone without linked antibodies (Beads), and probed with antibody against TMTC4. Endogenous TMTC4 was found to co-immunoprecipitate strongly with SERCA2b and weakly with Calnexin. Images are representative of 3 experiments.
Figure 6. Ca\(^{2+}\) dynamics in cochlear supporting cells. Ratiometric FURA-2 imaging was used to measure cytosolic [Ca\(^{2+}\)]. in WT and TMTC4 KO P3-5 cochlear cultures. A. Representative spontaneous intracellular Ca\(^{2+}\) wave in the inner sulcus of the organ of Corti. 7-μm square regions of interest in the inner and outer sulci were identified and FURA-2 excitation ratios (proportional to cytosolic Ca\(^{2+}\) concentration) measured. Ca\(^{2+}\) peaks were extracted and analyzed. B. Aggregate ratio timecourse for Ca\(^{2+}\) peaks normalized to baseline and peak maximum show identical initial kinetics and faster return to baseline in WT cochleae treated with the SERCA2B activator CDN1163 (CDN) + the SERCA2B inhibitor thapsigargin (TG) (N = 88 peaks) compared to TG (N = 65 peaks) alone, demonstrating the ability of known modulators of ER Ca\(^{2+}\) reuptake to affect Ca\(^{2+}\) peak decay time. C-E. 273 and 653 peaks were analyzed, respectively, from 6 WT and 6 KO cochleae. C. Peaks in TMTC4 KO cochleae (N=653) showed prolongation of return to baseline cytosolic Ca\(^{2+}\) level relative to WT controls (N=273). (B-C): Black bars: points at which aggregate ratios were statistically significantly different. Peak frequency (D, means +/- SE) and height (E; means +/- SE) were greater in KO cochleae. F. Decay time in WT cochleae was measured in dissecting solution (DS) and with drugs (CDN: 10 μM CDN1163; TG: 1 μM TG; and TG+CDN: 10 μM CDN1163 and 1 μM TG) as well as for TMTC4 KO cochleae in DS. Data indicate difference in means +/- SE of decay time
relative to that measured in WT cochleae in DS (number of peaks analyzed for each comparison in parentheses). * p < 0.01 re: DS in WT cochleae. # p < 0.0001 vs TG in WT cochleae (unpaired, two-tailed t-test for all comparisons).

**Figure 7.** Upregulation of the unfolded protein response (UPR) in Tmtc4 KO cells and cochlea.

A. mRNA levels of three genes, Chop, S-XBP1, and BiP, which represent the three principal arms of the UPR, were measured in fibroblasts treated with the SERCA2B inhibitor thapsigargin (TG). Treatment of fibroblasts from wild type (WT) and Tmtc4 knockout (KO) mice
with TG elicited an exaggerated upregulation of all three UPR effectors in KO compared to WT cells, as measured relative to expression of GAPDH and to unexposed KO and WT fibroblasts, respectively, by the \(2^{\Delta \Delta CT}\) method. **FACS** sorting of KO and WT cells positive for staining with antibody to CHOP shows a greater percentage of KO cells (29.9% vs 0.5% of WT cells) positive for CHOP expression. P2: gating set at 3 SD from the mean fluorescence for WT cells. **C.** mRNA levels of Chop, S-XBP1, and BiP were also upregulated to a greater extent in Tmtc4 KO cochlear explant cultures treated with TG compared to WT control cultures. TG treatment also induced apoptosis in KO cochlear cultures, as measured by the expression of Caspase 3. Data represent the means and SD of three independent experiments (culture dishes of confluent fibroblasts (A) or single cochlear cultures (C)). \(\ast \ p< 0.01; \ \ast \ast \ p<0.001\) by one-way ANOVA followed by Tukey multiple comparisons test.
**Figure 8.** UPR in noise-exposed WT mice.  

A. 8-wk-old WT FVB mice were exposed to 8-16 kHz octave-band white noise at 106 dB SPL for 120 minutes. Cochleae were removed two hours after exposure (Noise) or unexposed (No Noise). mRNA expression of Chop, S-XBP1, BiP, and caspase 3 is presented relative to expression of GAPDH and the average expression levels of control, unexposed cochleae by the $2^{ΔΔct}$ method. Data represent the means and SD of 4 (Chop, S-XBP1, and BiP) or 3 (caspase) cochleae in each condition. * p < 0.05; ** p< 0.01 by one-way ANOVA followed by Tukey multiple comparisons test.  

B. 8-wk-old WT FVB mice were exposed to noise, and ABR thresholds measured at 1, 7, and 14 days post-noise (PNE). IP injection of ISRIB (N = 11) 2h prior to noise exposure attenuated the hearing loss observed in vehicle-injected mice (N = 12). Data represent means and SD. * p < 0.05 by one-way ANOVA followed by Tukey multiple comparisons test.  

C. Whole-mount immunohistochemical staining for Myo7a (green, hair-cell marker) and actin (red, phalloidin) demonstrates 3 intact rows of outer hair cells (OHC) in control, non-exposed mice (top); significant OHC loss in mice exposed to noise and treated with vehicle (bottom); and minimal OHC loss in ISRIB-treated mice exposed to noise (middle). Images representative of 5 cochleae for each condition. D. OHC number was quantified in the mid-basal turn of the cochlea (N=5 cochleae for each condition, data presented as individual values with median and
interquartile range), demonstrating significantly greater OHC loss in vehicle-treated animals exposed to noise (Vehicle), compared to those treated with ISRIB, or non-noise-exposed controls. * p < 0.05 by Mann-Whitney rank-sum test.
Figure 9. Inverse complementation assay. **A.** As demonstrated in Figure 8, noise exposure induces expression of the pro-apoptotic UPR modulator Chop, and pharmacologic inhibition of Chop expression with ISRIB via ATF4 attenuates NIHL. **B.** In the genetic model of Tmtc4 deficiency, Tmtc4 KO cochlea demonstrate upregulation of Chop. In an inverse complementation model, we generated double KO mice with both Tmtc4 and CHOP deficiency and hypothesized that prevention of Chop expression would attenuate progressive postnatal hearing loss. **C.** ABR thresholds were measured for mice of the indicated genotypes for Tmtc4.
and Chop. Tmtc4 -/- mice were all tested at P19; Tmtc4 +/+ mice were all tested at P39 to ensure no long-term hearing loss associated with Chop deficiency alone. TMTC4 -/- mice showed elevated ABR thresholds compared to all TMTC4 +/- mice; among the TMTC4 -/- mice, CHOP -/- genotype was associated with improved hearing compared to CHOP +/- mice (black bar; p < 0.01 by unpaired two-tailed t-test. Data represent means and SD.)